Table 1A.
Demographics, medical history, clinical presentations, treatment and outcome.
| Parameter | COVID (N = 50) | Non-COVID (N = 67) | P-value = | |
|---|---|---|---|---|
| Median age, yr (IQR) | 31 | 31 | 0.85## | |
| Gender | M:F,27:23 | M:F;29:21 | ||
| Genotype | SS, n (%) | 10(20) | 28(56) | 0.07# |
| S/β0, n (%) | 29(58) | 16(32) | 0.01# | |
| Treated at | Home, n (%) | 16(32) | 20(29.8) | 0.85# |
| Admitted, n (%) | 34(68) | 47(70.2) | 0.99# | |
| Length of stay | Median, days (IQR) | 5(3.5-7.5) | 8(5-12) | 0.18## |
| Comorbidities | Previous infections, n (%) | 23(46) | 56(86.5) | 0.05# |
| Bacterial, n (%) | 18(36) | 47(70.1) | 0.04# | |
| Viral, n (%) | 13(26) | 37(55.2) | 0.04# | |
| Fungal, n (%) | 9(18) | 17(25.4) | 0.44# | |
| Median VOC/year, | 3 | 2 | 0.02## | |
| IQR | 1-6 | 2-12 | ||
| H/o Acute chest syndrome, n (%) | 37(74) | 39(58.2) | 0.41# | |
| Splenectomy, n (%) | 21(42) | 28(41.8) | 0.99# | |
| Cholecystectomy, n (%) | 16(32) | 15(22.4) | 0.37# | |
| Joint Necrosis, n (%) | 17(34) | 9(13.4) | 0.03# | |
| Sequestration, n (%) | 2(4) | 0(0) | 0.05# | |
| Splenomegaly, n (%) | 12(24) | 3(4.5) | 0.006# | |
| Hepatomegaly/Crisis, n (%) | 8(16) | 2(2.9) | 0.02# | |
| Transfusions-Intermittent, n (%) | 43(86) | 35(52.2) | 0.08# | |
| Transfusions-Regular, n (%) | 0(0) | 4(5.9) | 0.03# | |
| Presenting features | Pain, n (%) | 32 (64) | 55(84) | 0.023# |
| Fever, n (%) | 40(80) | 26(38.8) | 0.02# | |
| Cough n (%) | 23(46) | 13(19.4) | 0.02# | |
| Reduced saturation, n (%) | 8(16) | 15(22.4) | 0.47# | |
| Fatigue, n (%) | 14(28) | 3(4.5) | 0.002# | |
| Tachypnea, n (%) | 7(14) | 13(19.4) | 0.51# | |
| Pharyngitis, n (%) | 10(20) | 6(8.9) | 0.13# | |
| Headache, n (%) | 9(18) | 4(5.9) | 0.07# | |
| Abdominal pain, n (%) | 6(12) | 0(0) | 0.001# | |
| Anosmia, n (%) | 6(12) | 0(0) | 0.001# | |
| Clinical course | Mild, n (%) | 24(48) | 12(17.9) | 0.01# |
| Moderate, n (%) | 18(36) | 20(29.8) | 0.61# | |
| Severe, n (%) | 1(2) | 5(7.4) | 0.20# | |
| Treatment | Transfusions - Simple n (%) | 20(40) | 18(26.8) | 0.28# |
| - Red blood cell exchange | 6(12) | 9(13.4) | 0.84# | |
| Medication - HCQ therapy, n (%) | 6(12) | 4(5.9) | 0.29# | |
| - Azithromycin, n (%) | 24(48) | 16(23.8) | 0.05# | |
| - Dexamethasone, n(%) | 1(2) | 0() | 0.16# | |
| - Antiviral therapy, n (%) | 7(14) | 8(11.9) | 0.77# | |
| - Convalescent Plasma, n (%) | 2(4) | 0() | 0.05# | |
| - Antibiotics, n (%) | 34(68) | 30(44.7) | 0.18# | |
| LMWH, n (%) | 21(42) | 21(31.3) | 0.41# | |
| Outcome | ICU admission, n (%) | 2(4) | 4(5.9) | 0.64# |
| Ventilated, n (%) | 1(2) | 4(5.9) | 0.31# | |
| Acute chest syndrome, n (%) | 20(40) | 20(29.8) | 0.42# | |
| Mortality, n (%) | 2(4) | 3(6) | 0.98# | |
Key: IQR – Interquartile range, # Chi Square test (COVID group vs non-COVID group); HCQ – Hydroxychloroquine; LMWH – low molecular weight heparin.